Cargando…

A decline of LAMP- 2 predicts ursodeoxycholic acid response in primary biliary cirrhosis

Biochemical response to ursodeoxycholic acid (UDCA) in patients with primary biliary cirrhosis (PBC) is variable. We have previously reported that augmented expression of lysosome-associated membrane protein 2 (LAMP-2) was correlated with the severity of PBC. This study aimed to determine whether se...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Lu, Guo, Guan-ya, Wang, Jing-bo, Zhou, Xin-min, Yang, Qiong, Han, Zhe-yi, Li, Qiang, Zhang, Jing-wen, Cai, Yun, Ren, Xiao-li, Zhou, Xia, Chen, Rui-rui, Shi, Yong-quan, Han, Ying, Fan, Dai-ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403591/ https://www.ncbi.nlm.nih.gov/pubmed/25894308 http://dx.doi.org/10.1038/srep09772

Ejemplares similares

The Association between Bile Salt Export Pump Single-Nucleotide Polymorphisms and Primary Biliary Cirrhosis Susceptibility and Ursodeoxycholic Acid Response
por: Chen, Rui-rui, et al.
Publicado: (2014)

Combination Therapy of Ursodeoxycholic Acid and Corticosteroids for Primary Biliary Cirrhosis with Features of Autoimmune Hepatitis: A Meta-Analysis
por: Zhang, Yan, et al.
Publicado: (2013)

Ursodeoxycholic Acid Improves Bilirubin but Not Albumin in Primary Biliary Cirrhosis: Further Evidence for Nonefficacy
por: Tsochatzis, Emmanuel A., et al.
Publicado: (2013)

A Systems Model for Ursodeoxycholic Acid Metabolism in Healthy and Patients With Primary Biliary Cirrhosis
por: Zuo, P, et al.
Publicado: (2016)

Case–Control Study on Prednisolone Combined With Ursodeoxycholic Acid and Azathioprine in Pure Primary Biliary Cirrhosis With High Levels of Immunoglobulin G and Transaminases: Efficacy and Safety Analysis
por: Fang, Yu-Qing, et al.
Publicado: (2014)

Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis
por: Zhang, Yan, et al.
Publicado: (2015)

Treatment of primary biliary cirrhosis with ursodeoxycholic acid combined with traditional Chinese medicine: A protocol for systematic review and meta analysis
por: Chen, Xing, et al.
Publicado: (2020)

Combination therapy of ursodeoxycholic acid and glucocorticoid and (or) immunosuppressant in patients with primary biliary cholangitis: A meta-analysis
por: Wang, Zi-Long, et al.
Publicado: (2022)

Combination therapy of obeticholic acid and ursodeoxycholic acid in patients with primary biliary cholangitis who respond incompletely to ursodeoxycholic acid: a systematic review
por: Li, Xuan, et al.
Publicado: (2020)

Predictors of liver failure in primary biliary cirrhosis
por: Zhao, Pan, et al.
Publicado: (2015)

Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion
por: Yang, Chunmei, et al.
Publicado: (2022)

Ursodeoxycholic Acid Influences the Expression of p27(kip1) but Not FoxO1 in Patients with Non-Cirrhotic Primary Biliary Cirrhosis
por: Milkiewicz, Malgorzata, et al.
Publicado: (2014)

Treatment of ursodeoxycholic acid with glucocorticoids and immunosuppressants may improve the long-term survival rate in primary biliary cholangitis patients
por: Wang, Zi-Long, et al.
Publicado: (2022)

Predictive Model of Ursodeoxycholic Acid Treatment Response in Primary Biliary Cholangitis
por: Shu, Yanyun, et al.
Publicado: (2021)

A randomized, controlled trial on fenofibrate in primary biliary cholangitis patients with incomplete response to ursodeoxycholic acid
por: Li, Chunlei, et al.
Publicado: (2022)

Fibrates for the Treatment of Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid: An Exploratory Study
por: Cançado, Guilherme Grossi Lopes, et al.
Publicado: (2022)

An enhanced level of LAMP-2A participates in CD4(+)T cell hyperactivity in patients with primary biliary cholangitis
por: Sun, Keshuai, et al.
Publicado: (2021)

Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid
por: Ding, Dawei, et al.
Publicado: (2022)

Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study
por: Papastergiou, V, et al.
Publicado: (2013)

Ursodeoxycholic Acid Is Conjugated with Taurine to Promote Secretin-Stimulated Biliary Hydrocholeresis in the Normal Rat
por: Úriz, Miriam, et al.
Publicado: (2011)

Looking Into the Crystal Ball: Predicting Non-response to Ursodeoxycholic Acid in Primary Biliary Cholangitis
por: Zimmer, Vincent, et al.
Publicado: (2016)

Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis
por: Zhu, Gui-Qi, et al.
Publicado: (2015)

Primary biliary cirrhosis
por: Kumagi, Teru, et al.
Publicado: (2008)

BILIARY CIRRHOSIS IN THE RABBIT
por: Richardson, Maurice L.
Publicado: (1911)

Primary biliary cirrhosis
por: Hohenester, Simon, et al.
Publicado: (2009)

Infantile Biliary Cirrhosis
por: Singh, Bhup
Publicado: (1911)

Infantile Biliary Cirrhosis
por: Forsyth, W. Leonard
Publicado: (1937)

Infantile Biliary Cirrhosis
por: Ganguli, Satkari
Publicado: (1917)

External validation of the United Kingdom‐primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid
por: Cheung, Angela C., et al.
Publicado: (2018)

Concomitant Sjögren's Syndrome Was Not Associated with a Poorer Response or Outcomes in Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cholangitis
por: Ni, Ping, et al.
Publicado: (2019)

Combination therapy of ursodeoxycholic acid and budesonide for PBC–AIH overlap syndrome: a meta-analysis
por: Zhang, Huawei, et al.
Publicado: (2015)

Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis
por: Martinez-Gili, Laura, et al.
Publicado: (2023)

Senescence and senotherapies in biliary atresia and biliary cirrhosis
por: Jannone, Giulia, et al.
Publicado: (2023)

Cholangiopathy and Biliary Fibrosis in Cyp2c70-Deficient Mice Are Fully Reversed by Ursodeoxycholic Acid
por: de Boer, Jan Freark, et al.
Publicado: (2020)

Effectiveness of bezafibrate and ursodeoxycholic acid in patients with primary biliary cholangitis: a meta-analysis of randomized controlled trials
por: Agrawal, Rohit, et al.
Publicado: (2019)

Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis
por: Yin, Qin, et al.
Publicado: (2015)

Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis
por: Harms, Maren H, et al.
Publicado: (2020)

Biliary secretion of endotoxin and pathogenesis of primary biliary cirrhosis.
por: Sakisaka, S., et al.
Publicado: (1997)

Evaluation of the United Kingdom‐primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population
por: Alomari, Mohammad, et al.
Publicado: (2019)

Clinical Outcomes and Validation of Ursodeoxycholic Acid Response Scores in Patients with Korean Primary Biliary Cholangitis: A Multicenter Cohort Study
por: Chang, Jong-In, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d8mke2828c1npi9h550qusl61m